Since inception, Seattle Genetics has focused on treating and helping patients struggling with cancer. It has developed and commercialized advanced antibody-based therapies for treating cancer. The firm is a biotechnological giant when it comes to designing and developing antibody-drug conjugates (ADC. ADC is a technology created to optimize the targeting capability of monoclonal antibodies to dispense cell-killing agents specifically to cancer cells. Seattle is developing ADCs, which do not harm non-targeted cell and hence decrease the various toxic effects associated with traditional chemotherapy while improving antitumor activity.
Approved and Commercialized ADCETRIS
ADCETRIS is the first ADC produced and commercialized by Seattle Genetics. The firm has collaborated with Takeda Pharmaceutical Company LTD to commercialize ADCETRIS. The medication can be purchased from licensed pharmaceutical stores in over 65 countries. Dr. Siegall is leading a team of researchers in carrying out a thorough clinical development program to evaluate if ADCETRIS can become the basis for treating CD30-expressing lymphomas. Examples of these CD30-expressing lymphomas include Hodgkin lymphoma, mature T-cell lymphomas, cutaneous T-cell lymphomas, and B-cell lymphomas.
Under the partnership with Takeda, Seattle Genetics holds full ADCETRIS’ commercialization rights in Canada and the U.S. On the other hand, Takeda holds special rights in all other nations. Seattle is advancing a diverse product pipeline with a special focus on solid tumors and hematologic malignancies.
An overview on Dr. Clay Siegall
Dr. Siegall is a passionate scientist, an innovator, and a leader in the development of antibody-based cancer therapies. Siegall attended the University of Maryland and acquired a degree in zoology. He also served at Bristol-Myers Squibb Pharmaceutical Research Institute for nearly six years (1991-1997).
Dr. Siegall took his scientific career to another level in 1998 by cofounding Seattle Genetics. Currently, he is the Board Chairman and CEO. He has guided the firm in building a dynamic pipeline of antibody-based therapies for fighting cancer. In fact, Seattle’s first commercialized medication, ADCETRIS, got approval from FDA in 2011.